{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:51:41Z","timestamp":1793987501617,"version":"4.8.0"},"reference-count":30,"publisher":"BMJ","license":[{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","award":["3000268822, 3000747780"],"award-info":[{"award-number":["3000268822, 3000747780"]}],"id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Stichting Amsterdam-Dinner Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"M.A.C. Aids Fund","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["522002003"],"award-info":[{"award-number":["522002003"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"H-TEAM","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","award":["PHNL\/JAN\/0714\/0005b\/1912fde"],"award-info":[{"award-number":["PHNL\/JAN\/0714\/0005b\/1912fde"]}],"id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Aidsfonds Netherlands","award":["2013169"],"award-info":[{"award-number":["2013169"]}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["CONL-276-4222, CO-US-276-1712"],"award-info":[{"award-number":["CONL-276-4222, CO-US-276-1712"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gilead Sciences Europe Ltd","award":["PA-HIV-PREP-16-0024"],"award-info":[{"award-number":["PA-HIV-PREP-16-0024"]}]},{"DOI":"10.13039\/501100007192","name":"Rijksinstituut voor Volksgezondheid en Milieu","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100007192","id-type":"DOI","asserted-by":"publisher"}]},{"name":"GGD research funds","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Sex Transm Infect"],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Adherence is key to the effectiveness of oral pre-exposure prophylaxis (PrEP) to prevent HIV. Therefore, we aimed to explore factors associated with adherence to daily PrEP (dPrEP).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Men who have sex with men (MSM) using dPrEP (emtricitabine\/tenofovir disoproxil) within the Amsterdam PrEP demonstration project at the Public Health Service of Amsterdam, provided dried blood spots (DBS) 12 and 24 months after PrEP initiation. From DBS, we determined intracellular tenofovir diphosphate (TFV-DP) concentrations to assess adherence; TFV-DP \u2265700 fmol\/punch was considered adequate. We assessed associations of sociodemographic, clinical and behavioural characteristics with TFV-DP concentrations using multivariable linear regression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 263 participants who attended 12-month or 24-month study visits while on dPrEP, 257 (97.7%) provided DBS at one or both visits (492 DBS in total). Median TFV-DP concentration was 1299 (IQR 1021\u20131627) fmol\/punch (12 months: 1332 (1087\u20131687); 24 months: 1248 (929\u20131590]). Higher TFV-DP concentrations were associated with: older age (p=0.0008), condomless anal sex with a casual partner in 6 months preceding PrEP initiation (+166 fmol\/punch; 95% CI 36.5 to 296) and using a mobile application providing visualised feedback on PrEP use and sexual behaviour (+146 fmol\/punch; 95% CI 28.1 to 263). Lower TFV-DP concentrations were associated with longer duration of PrEP use (24 vs 12 months; \u221291.5 fmol\/punch; 95% CI \u2212155 to \u221228.1). Time-updated number of sex partners, diagnosed STIs and chemsex were not associated with TFV-DP concentrations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Overall, TFV-DP concentrations were high among MSM using dPrEP, indicating excellent adherence. Especially older participants, those who reported condomless anal sex with a casual partner prior to PrEP initiation and those who used an app with visualised feedback showed higher levels of adherence. As TFV-DP concentrations had decreased slightly at 2 years of PrEP use when compared with 1 year, we emphasise the importance of adherence counselling to those who continue using PrEP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p>NL5413.<\/jats:p><\/jats:sec>","DOI":"10.1136\/sextrans-2022-055499","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T17:22:05Z","timestamp":1662398525000},"page":"sextrans-2022-055499","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Determinants of adherence to daily PrEP measured as intracellular tenofovir diphosphate concentrations over 24 months of follow-up among men who have sex with men"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0881-5680","authenticated-orcid":false,"given":"Mark AM","family":"van den Elshout","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0512-2109","authenticated-orcid":false,"given":"Elske","family":"Hoornenborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"Coyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udi","family":"Davidovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9784-547X","authenticated-orcid":false,"given":"Henry JC","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Prins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4903-7002","authenticated-orcid":false,"given":"Maarten F","family":"Schim van der Loeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,9,5]]},"reference":[{"key":"2023053110251911000_sextrans-2022-055499v2.1","unstructured":"van Sighem AI , FWNM W , Boyd A , Smit C , Matser A , van der Valk M . Monitoring report 2021. Human immunodeficiency virus (HIV) infection in the Netherlands. Amsterdam Stichting hiv monitoring; 2021."},{"key":"2023053110251911000_sextrans-2022-055499v2.2","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2217\/fvl-2018-0084","article-title":"Preparing for the unexpected: mechanisms and management of HIV pre-exposure prophylaxis failure","volume":"13","author":"Dashwood","year":"2018","journal-title":"Future Virol"},{"key":"2023053110251911000_sextrans-2022-055499v2.3","unstructured":"WHO . WHO implementation tool for pre-exposure prophylaxis of HIV infection. Geneva, Switzerland World Health Organization; 2017."},{"key":"2023053110251911000_sextrans-2022-055499v2.4","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01710-17","article-title":"Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in dried blood spots following directly observed therapy","volume":"62","author":"Anderson","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023053110251911000_sextrans-2022-055499v2.5","doi-asserted-by":"publisher","DOI":"10.1089\/AID.2012.0089"},{"key":"2023053110251911000_sextrans-2022-055499v2.6","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25105","article-title":"Men who have sex with men more often chose daily than event-driven use of pre-exposure prophylaxis: baseline analysis of a demonstration study in Amsterdam","volume":"21","author":"Hoornenborg","year":"2018","journal-title":"J Int AIDS Soc"},{"key":"2023053110251911000_sextrans-2022-055499v2.7","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/QAD.0000000000002949","article-title":"Improving adherence to daily preexposure prophylaxis among MSM in Amsterdam by providing feedback via a mobile application","volume":"35","author":"van den Elshout","year":"2021","journal-title":"AIDS"},{"key":"2023053110251911000_sextrans-2022-055499v2.8","doi-asserted-by":"publisher","DOI":"10.1007\/s10508-009-9483-9"},{"key":"2023053110251911000_sextrans-2022-055499v2.9","doi-asserted-by":"publisher","DOI":"10.1207\/s15327752jpa6203_1"},{"key":"2023053110251911000_sextrans-2022-055499v2.10","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-8-10"},{"key":"2023053110251911000_sextrans-2022-055499v2.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00056-2"},{"key":"2023053110251911000_sextrans-2022-055499v2.12","unstructured":"Babor TF , Higgins-Biddle JC , Saunders JB . AUDIT: the alcohol use disorders identification test. guidelines for use in primary care. Geneva World Health Organization; 2001."},{"key":"2023053110251911000_sextrans-2022-055499v2.13","doi-asserted-by":"publisher","DOI":"10.1159\/000081413"},{"key":"2023053110251911000_sextrans-2022-055499v2.14","doi-asserted-by":"crossref","first-page":"100505","DOI":"10.1016\/j.eclinm.2020.100505","article-title":"Changes in mental health and drug use among men who have sex with men using daily and event-driven pre-exposure prophylaxis: results from a prospective demonstration project in Amsterdam, the Netherlands","volume":"26","author":"Achterbergh","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2023053110251911000_sextrans-2022-055499v2.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2016.01.038"},{"key":"2023053110251911000_sextrans-2022-055499v2.16","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1093\/jac\/dkz184","article-title":"Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir\/sofosbuvir","volume":"74","author":"Brooks","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023053110251911000_sextrans-2022-055499v2.17","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/QAI.0000000000001598","article-title":"Medication adherence in a nationwide cohort of Veterans initiating pre-exposure prophylaxis (PreP) to prevent HIV infection","volume":"77","author":"van Epps","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023053110251911000_sextrans-2022-055499v2.18","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30008-0"},{"key":"2023053110251911000_sextrans-2022-055499v2.19","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s10461-018-2353-5","article-title":"Predictors of daily adherence to HIV pre-exposure prophylaxis in gay\/bisexual men in the prelude demonstration project","volume":"23","author":"Vaccher","year":"2019","journal-title":"AIDS Behav"},{"key":"2023053110251911000_sextrans-2022-055499v2.20","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/QAI.0000000000001965","article-title":"Factors associated with sex-related pre-exposure prophylaxis adherence among men who have sex with men in New York City in HPTN 067","volume":"80","author":"Mannheimer","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023053110251911000_sextrans-2022-055499v2.21","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1097\/QAD.0000000000002970","article-title":"Adherence to daily HIV pre-exposure prophylaxis in a large-scale implementation study in New South Wales, Australia","volume":"35","author":"Jin","year":"2021","journal-title":"AIDS"},{"key":"2023053110251911000_sextrans-2022-055499v2.22","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1089\/aid.2020.0108","article-title":"Individualized adherence benchmarks for HIV pre-exposure prophylaxis","volume":"37","author":"Ibrahim","year":"2021","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2023053110251911000_sextrans-2022-055499v2.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.12.013"},{"key":"2023053110251911000_sextrans-2022-055499v2.24","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30136-5"},{"key":"2023053110251911000_sextrans-2022-055499v2.25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2174\/1874613601711010119","article-title":"mHealth interventions to support self-management in HIV: a systematic review","volume":"11","author":"Cooper","year":"2017","journal-title":"Open AIDS J"},{"key":"2023053110251911000_sextrans-2022-055499v2.26","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2014.0156"},{"key":"2023053110251911000_sextrans-2022-055499v2.27","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1016\/S2352-3018(20)30307-6","article-title":"Effect of SMS reminders on PrEP adherence in young Kenyan women (MPYA study): a randomised controlled trial","volume":"8","author":"Haberer","year":"2021","journal-title":"Lancet HIV"},{"key":"2023053110251911000_sextrans-2022-055499v2.28","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25733","article-title":"Imperfect adherence in real life: a prevention-effective perspective on adherence to daily and event-driven HIV pre-exposure prophylaxis among men who have sex with men\u2013a prospective cohort study in Taiwan","volume":"24","author":"Wu","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"2023053110251911000_sextrans-2022-055499v2.29","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25708","article-title":"Adherence to event-driven HIV PrEP among men who have sex with men in Amsterdam, the Netherlands: analysis based on online diary data, 3-monthly questionnaires and intracellular TFV-DP","volume":"24","author":"Jongen","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"2023053110251911000_sextrans-2022-055499v2.30","doi-asserted-by":"crossref","first-page":"100650","DOI":"10.1016\/j.eclinm.2020.100650","article-title":"Understanding pre-exposure prophylaxis (PrEP) regimen use: switching and discontinuing daily and event-driven PreP among men who have sex with men","volume":"29-30","author":"Coyer","year":"2020","journal-title":"EClinicalMedicine"}],"container-title":["Sexually Transmitted Infections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/sextrans-2022-055499","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T18:00:07Z","timestamp":1685556007000},"score":1,"resource":{"primary":{"URL":"https:\/\/sti.bmj.com\/lookup\/doi\/10.1136\/sextrans-2022-055499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,5]]},"references-count":30,"alternative-id":["10.1136\/sextrans-2022-055499"],"URL":"https:\/\/doi.org\/10.1136\/sextrans-2022-055499","relation":{},"ISSN":["1368-4973","1472-3263"],"issn-type":[{"value":"1368-4973","type":"print"},{"value":"1472-3263","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,5]]}}}